Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777584 | 1.00 | CA1 (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL21239569 | 0.89 | TSHR (0.56) | CA1CA2CA7CA9TSHR | |
| SCHEMBL18653736 | 0.88 | CA1 (0.53) | CA1CA2CA7CA9TSHR | |
| SCHEMBL12444919 | 0.84 | TSHR (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL12444920 | 0.84 | TSHR (0.50) | CA1CA2CA7CA9TSHR | |
| SCHEMBL2963549 | 0.82 | TSHR (0.48) | CA1CA2CA7CA9TSHR | |
| SCHEMBL1132896 | 0.82 | TSHR (0.48) | CA1CA2CA7CA9TSHR | |
| SCHEMBL1132897 | 0.82 | TSHR (0.48) | CA1CA2CA7CA9TSHR | |
| SCHEMBL19699720 | 0.82 | TSHR (0.48) | CA1CA2CA7CA9TSHR | |
| SCHEMBL2963542 | 0.82 | TSHR (0.48) | CA1CA2CA7CA9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| US-9079839-B2 | Methods for preparation of pharmaceutical intermediates of aliskiren | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2015-07-14 | — | — | US | disclosed |
| CN-103539639-B | Method for preparing key intermediate of medicament | CHANGZHOU PHARMACEUTICAL FACTORY | 2015-05-20 | — | — | CN | disclosed |
| CN-103539639-A | Method for preparing key intermediate of medicament | Changzhou pharmaceutical factory co ltd | 2014-01-29 | — | — | CN | disclosed |
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2013-09-05 | — | — | US | disclosed |
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2013-09-05 | — | — | US | disclosed |
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | CHANGZHOU PHARMACEUTICAL FACTORY (CN) | 2013-09-05 | — | — | US | disclosed |
| CN-102001920-B | Preparation method of drug intermediate | CHANGZHOU PHARMACEUTICAL FACTORY | 2013-05-15 | — | — | CN | disclosed |
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084485-B2 | 6-(aminoalkyl)indazoles | VITAE PHARMACEUTICALS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | VITAE PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2007120523-A2 | 6-(AMINOALKYL)INDAZOLES | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331287-A1 | 6-(Aminoalkyl)Indazoles | REN, AGTR1, AGTR2 | CA1 4586/4885CA2 598/4885CA7 1259/4885 |
| US-20130231509-A1 | METHODS FOR PREPARATION OF PHARMACEUTICAL INTERMEDIATES OF ALISKIREN | VRK2, VRK1, LPXN | CA1 2021/4885CA2 967/4885CA7 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.